[go: up one dir, main page]

HRP20201399T1 - Novi modulatori i postupci njihove uporabe - Google Patents

Novi modulatori i postupci njihove uporabe Download PDF

Info

Publication number
HRP20201399T1
HRP20201399T1 HRP20201399TT HRP20201399T HRP20201399T1 HR P20201399 T1 HRP20201399 T1 HR P20201399T1 HR P20201399T T HRP20201399T T HR P20201399TT HR P20201399 T HRP20201399 T HR P20201399T HR P20201399 T1 HRP20201399 T1 HR P20201399T1
Authority
HR
Croatia
Prior art keywords
seq
residues
variable region
antibody
chain variable
Prior art date
Application number
HRP20201399TT
Other languages
English (en)
Inventor
Orit Foord
Scott J. Dylla
Robert A. Stull
Alex Bankovich
Alexandra Leida Liana LAZETIC
Jeffrey Bernstein
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/050451 external-priority patent/WO2012031280A2/en
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of HRP20201399T1 publication Critical patent/HRP20201399T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (19)

1. Kimerno, CDR-kalemljeno, humanizirano ili rekombinantno ljudsko protutijelo, ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski PTK7 i pritom obuhvaća varijabilne regije lakog i teškog lanca, pri čemu: (a) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 24-34 od SEQ ID NO:62 za VL CDR1, ostaci 50-56 od SEQ ID NO:62 za VL CDR2 i ostaci 89-97 od SEQ ID NO:62 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 31-35 od SEQ ID NO:63 za VH CDR1, ostaci 50-65 od SEQ ID NO:63 za VH CDR2 i ostaci 95-102 od SEQ ID NO:63 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Kabat shemom; (b) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 23-34 od SEQ ID NO:62 za VL CDR1, ostaci 50-56 od SEQ ID NO:62 za VL CDR2 i ostaci 89-97 od SEQ ID NO:62 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 26-32 od SEQ ID NO:63 za VH CDR1, ostaci 50-58 od SEQ ID NO:63 za VH CDR2 i ostaci 95-102 od SEQ ID NO:63 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Chothia shemom; ili (c) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-36 od SEQ ID NO:62 za VL CDR1, ostaci 46-55 od SEQ ID NO:62 za VL CDR2 i ostaci 89-96 od SEQ ID NO:62 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-35 od SEQ ID NO:63 za VH CDR1, ostaci 47-58 od SEQ ID NO:63 za VH CDR2 i ostaci 93-101 od SEQ ID NO:63 za VH CDR3, pri čemu je CDR-numeriranje u skladu s MacCallum shemom.
2. Kimerno, CDR-kalemljeno, humanizirano ili rekombinantno ljudsko protutijelo, ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski PTK7 i pritom obuhvaća varijabilne regije lakog i teškog lanca, pri čemu: (a) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 24-34 od SEQ ID NO:64 za VL CDR1, ostaci 50-56 od SEQ ID NO:64 za VL CDR2 i ostaci 89-97 od SEQ ID NO:64 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 31-35 od SEQ ID NO:65 za VH CDR1, ostaci 50-65 od SEQ ID NO:65 za VH CDR2 i ostaci 95-102 od SEQ ID NO:65 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Kabat shemom; (b) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 23-34 od SEQ ID NO:64 za VL CDR1, ostaci 50-56 od SEQ ID NO:64 za VL CDR2 i ostaci 89-97 od SEQ ID NO:64 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 26-32 od SEQ ID NO:65 za VH CDR1, ostaci 50-58 od SEQ ID NO:65 za VH CDR2 i ostaci 95-102 od SEQ ID NO:65 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Chothia shemom; ili (c) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-36 od SEQ ID NO:64 za VL CDR1, ostaci 46-55 od SEQ ID NO:64 za VL CDR2 i ostaci 89-96 od SEQ ID NO:64 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-35 od SEQ ID NO:65 za VH CDR1, ostaci 47-58 od SEQ ID NO:65 za VH CDR2 i ostaci 93-101 od SEQ ID NO:65 za VH CDR3, pri čemu je CDR-numeriranje u skladu s MacCallum shemom.
3. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1 ili 2, naznačeno time, da obuhvaća: (a) varijabilnu regiju lakog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:63; ili (b) varijabilnu regiju lakog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:65.
4. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1, naznačeno time, da obuhvaća varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:63.
5. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 2, naznačeno time, da obuhvaća varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:65.
6. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da je to neutralizirajuće, iscrpljujuće protutijelo, i/ili je internalizirajuće protutijelo.
7. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time, da se specifično veže na PTK7 izooblik koji je odabran iz skupine koju čine: izooblik a, izooblik b, izooblik c i izooblik d.
8. Konjugat protutijela, naznačen time, da obuhvaća protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, gdje je to protutijelo konjugirano, povezano, ili na neki drugi način udruženo sa citotoksičnim sredstvom.
9. Farmaceutski pripravak, naznačen time, da obuhvaća protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela u skladu s patentnim zahtjevom 8.
10. Nukleinska kiselina, naznačena time, da kodira varijabilnu regiju teškog lanca i/ili varijabilnu regiju lakog lanca protutijela ili njegovog fragmenta koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7.
11. Vektor ili stanica domaćina, naznačeni time, da sadrže nukleinsku kiselinu u skladu s patentnim zahtjevom 10.
12. Stanica, naznačena time, da obuhvaća protutijelo koje se specifično veže na ljudski PTK7, pri čemu stanica obuhvaća jednu ili više nukleinskih kiselina koje kodiraju sljedeće: (a) varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:63; ili (b) varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:65.
13. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju kao farmaceutski proizvod.
14. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da se upotrebljava u detektiranju, dijagnosticiranju ili nadgledanju poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
15. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju u liječenju poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, dok je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
16. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju u smanjivanju frekvencije stanica koje iniciraju tumor kod pojedinca.
17. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da se upotrebljava u postupku in vivo za detektiranje, dijagnosticiranje ili nadgledanje poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
18. Postupak in vivo za detektiranje, dijagnosticiranje ili nadgledanje poremećaja koji je povezan s PTK7, naznačen time, da se provodi uporabom protutijela ili njegovog fragmenta koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
19. Protutijelo ili njegov fragment koji veže antigen, za uporabu u skladu s bilo kojim od patentnih zahtjeva 14 do 15 ili 17, ili konjugat protutijela za uporabu u skladu s patentnim zahtjevom 15, ili postupak prema patentnom zahtjevu 18, naznačeni time, da poremećaj koji je povezan s PTK7 je rak.
HRP20201399TT 2011-02-18 2012-02-17 Novi modulatori i postupci njihove uporabe HRP20201399T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161444614P 2011-02-18 2011-02-18
PCT/US2011/050451 WO2012031280A2 (en) 2010-09-03 2011-09-02 Identification and enrichment of cell subpopulations
PCT/US2012/025726 WO2012112943A1 (en) 2011-02-18 2012-02-17 Novel modulators and methods of use
EP12705776.8A EP2675827B1 (en) 2011-02-18 2012-02-17 Novel modulators and methods of use

Publications (1)

Publication Number Publication Date
HRP20201399T1 true HRP20201399T1 (hr) 2020-11-27

Family

ID=46672972

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201399TT HRP20201399T1 (hr) 2011-02-18 2012-02-17 Novi modulatori i postupci njihove uporabe

Country Status (32)

Country Link
US (3) US9409995B2 (hr)
EP (2) EP2675827B1 (hr)
JP (2) JP6296796B2 (hr)
KR (1) KR102022734B1 (hr)
CN (2) CN103547597B (hr)
AR (1) AR085281A1 (hr)
AU (3) AU2012219313C1 (hr)
BR (1) BR112013021134B1 (hr)
CA (1) CA2827637C (hr)
CO (1) CO6791571A2 (hr)
CY (1) CY1123551T1 (hr)
DK (1) DK2675827T3 (hr)
ES (1) ES2829206T3 (hr)
HR (1) HRP20201399T1 (hr)
HU (1) HUE050657T2 (hr)
IL (3) IL228018A (hr)
LT (1) LT2675827T (hr)
MX (1) MX356434B (hr)
MY (1) MY173880A (hr)
PE (2) PE20181076A1 (hr)
PH (2) PH12013501710A1 (hr)
PL (1) PL2675827T3 (hr)
PT (1) PT2675827T (hr)
RS (1) RS60841B1 (hr)
RU (2) RU2627176C2 (hr)
SA (1) SA112330278B1 (hr)
SG (2) SG10201603926SA (hr)
SI (1) SI2675827T1 (hr)
SM (1) SMT202000556T1 (hr)
TW (2) TWI696635B (hr)
WO (1) WO2012112943A1 (hr)
ZA (1) ZA201306958B (hr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2689787A1 (en) 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061340A1 (en) * 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
JP6454547B2 (ja) * 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
WO2015001078A1 (en) * 2013-07-04 2015-01-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A new fusion protein to target and treat acute myloid leukemia cells
WO2015157976A1 (zh) * 2014-04-17 2015-10-22 深圳迈瑞生物医疗电子股份有限公司 细胞分析方法和系统、装置
US9777070B2 (en) * 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
KR20190132665A (ko) 2017-03-23 2019-11-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-C5a 항체 및 이의 용도
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
BR112020016859A2 (pt) 2018-02-28 2020-12-29 Pfizer Inc. Variantes de il-15 e usos da mesma
JP7057843B2 (ja) 2018-05-23 2022-04-20 ファイザー・インク ＧＵＣＹ２ｃに特異的な抗体及びその使用
US11434292B2 (en) 2018-05-23 2022-09-06 Pfizer Inc. Antibodies specific for CD3 and uses thereof
CN112243381B (zh) 2018-06-14 2025-02-07 2赛文缇生物公司 抗bcma car抗体、缀合物和使用方法
WO2020014175A1 (en) * 2018-07-10 2020-01-16 Children's Medical Center Corporation Methods and compositions for analyzing immortalized megakaryocyte progenitor cell lines and platelet-like particles derived therefrom
CA3118830A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
JP2023506262A (ja) * 2019-12-16 2023-02-15 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法
PH12022551298A1 (en) 2019-12-17 2023-11-20 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof
WO2021124096A1 (en) 2019-12-18 2021-06-24 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
JP7515204B2 (ja) * 2020-02-27 2024-07-12 エスアンドティー バイオメッド カンパニー リミテッド マトリックスメタロプロテアーゼ１のモノクローナル抗体、その検出キット及び検出方法
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
KR20230008197A (ko) 2020-05-13 2023-01-13 화이자 인코포레이티드 암을 치료하기 위한 방법, 요법 및 용도
KR102678735B1 (ko) * 2020-07-16 2024-06-26 연세대학교 산학협력단 Ptk7에 특이적으로 결합하는 항체 및 이의 용도
KR20230022246A (ko) 2020-07-17 2023-02-14 화이자 인코포레이티드 치료 항체 및 그의 용도
TW202224703A (zh) 2020-09-14 2022-07-01 美商輝瑞股份有限公司 治療癌症之方法、治療劑及用途
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2023108101A1 (en) * 2021-12-09 2023-06-15 Emory University Antibodies that inhibit glycoprotein ib-ix mediated platelet signaling and uses in managing bleeding conditions
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
EP4540278A1 (en) 2022-06-17 2025-04-23 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
EP4551296A1 (en) 2022-07-05 2025-05-14 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024080325A1 (ja) * 2022-10-14 2024-04-18 Jsr株式会社 抗体及びその使用
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024193679A1 (en) * 2023-03-23 2024-09-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Antibodies and uses thereof
WO2024209339A1 (en) 2023-04-05 2024-10-10 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2025032521A1 (en) 2023-08-10 2025-02-13 Pfizer Inc. Methods, therapies and uses for treating cancer
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265551A (en) 1977-07-13 1981-05-05 U.S. Philips Corporation Drive for transporting and reversing an ink ribbon, and for withdrawing the printing head in printing devices
US4111824A (en) 1977-07-21 1978-09-05 Gulf Research & Development Co. Liquid dielectric composition based on a fraction derived from the alkylation product of benzene with ethylene
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ES2096749T3 (es) 1990-12-14 1997-03-16 Cell Genesys Inc Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
WO1994004670A1 (en) 1992-08-26 1994-03-03 President And Fellows Of Harvard College Use of the cytokine ip-10 as an anti-tumor agent
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
JP2000508522A (ja) 1996-03-22 2000-07-11 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド アポトーシス誘導分子ｉｉ
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ES2303358T3 (es) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
WO2003075957A1 (en) 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
JP4884224B2 (ja) 2003-05-09 2012-02-29 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
RU2366716C2 (ru) * 2003-10-24 2009-09-10 Эсбатек Аг Способ идентификации и/или проверки ингибиторов рецепторных тирозинкиназ
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
JP2008510007A (ja) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたＥｐｈ受容体Ｆｃ変異体
US8222253B2 (en) 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
CN101360761B (zh) 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
US8058252B2 (en) 2005-12-30 2011-11-15 Institut Gustave Roussy Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
MX2008015492A (es) 2006-06-06 2009-02-12 Univ Tennessee Res Foundation Composiciones enriquecidas en celulas madre neoplasicas y metodos que las contienen.
LT3207941T (lt) 2006-09-07 2020-04-10 Scott & White Memorial Hospital Būdai ir kompozicijos difterijos toksino ir interleukino 3 konjugatų pagrindu
US8309354B2 (en) 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
WO2008149803A1 (ja) * 2007-06-06 2008-12-11 The University Of Tokyo 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法
EP2190481B1 (en) 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
CN101842116A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 结合igf-1r多个表位的组合物
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
WO2009070767A2 (en) * 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
EP2229187A2 (en) * 2007-11-30 2010-09-22 Bristol-Myers Squibb Company Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
US8384551B2 (en) 2008-05-28 2013-02-26 MedHab, LLC Sensor device and method for monitoring physical stresses placed on a user
EP2207803B1 (en) 2008-06-25 2013-05-01 Korea Research Institute of Bioscience and Biotechnology Cd9-specific human antibodies
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
WO2010078526A1 (en) * 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US8788213B2 (en) 2009-01-12 2014-07-22 Intrexon Corporation Laser mediated sectioning and transfer of cell colonies
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
FR2964148A1 (fr) 2010-08-30 2012-03-02 Peugeot Citroen Automobiles Sa Boite de degazage destinee au circuit de refroidissement d'un moteur thermique de vehicule automobile
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
EP2689787A1 (en) 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
US9777070B2 (en) * 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
US20190209704A1 (en) 2014-10-20 2019-07-11 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions and methods of use
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
SG10201603926SA (en) 2016-07-28
PH12013501710A1 (en) 2013-10-07
TWI696635B (zh) 2020-06-21
CA2827637A1 (en) 2012-08-30
CN107056945A (zh) 2017-08-18
PE20141028A1 (es) 2014-08-30
HUE050657T2 (hu) 2021-01-28
JP2018104409A (ja) 2018-07-05
AU2019201258A1 (en) 2019-03-14
AU2012219313C1 (en) 2017-05-25
IL228018A (en) 2017-09-28
ZA201306958B (en) 2022-03-30
CN103547597A (zh) 2014-01-29
RS60841B1 (sr) 2020-10-30
SA112330278B1 (ar) 2015-10-09
BR112013021134A8 (pt) 2017-07-11
AR085281A1 (es) 2013-09-18
US20140105888A1 (en) 2014-04-17
PT2675827T (pt) 2020-10-29
PL2675827T3 (pl) 2021-01-25
DK2675827T3 (da) 2020-09-07
US20160272723A1 (en) 2016-09-22
BR112013021134B1 (pt) 2022-12-27
JP6296796B2 (ja) 2018-03-28
SG192816A1 (en) 2013-09-30
CA2827637C (en) 2020-08-11
SMT202000556T1 (it) 2020-11-10
MY173880A (en) 2020-02-26
KR102022734B1 (ko) 2019-09-19
EP2675827A1 (en) 2013-12-25
US9409995B2 (en) 2016-08-09
AU2012219313A1 (en) 2013-05-02
CY1123551T1 (el) 2022-03-24
MX2013009541A (es) 2014-04-30
PH12018500452A1 (en) 2019-11-18
RU2013141976A (ru) 2015-03-27
JP2014511179A (ja) 2014-05-15
EP3763388A1 (en) 2021-01-13
RU2017126476A (ru) 2019-01-31
ES2829206T3 (es) 2021-05-31
TWI624476B (zh) 2018-05-21
MX356434B (es) 2018-05-29
IL228018A0 (en) 2013-09-30
LT2675827T (lt) 2020-10-26
IL263020A (en) 2018-12-31
WO2012112943A1 (en) 2012-08-23
SI2675827T1 (sl) 2020-11-30
US20180162952A1 (en) 2018-06-14
EP2675827B1 (en) 2020-08-05
AU2012219313B2 (en) 2017-02-02
RU2627176C2 (ru) 2017-08-03
US10836831B2 (en) 2020-11-17
TW201800421A (zh) 2018-01-01
IL254062B (en) 2018-11-29
NZ615285A (en) 2015-09-25
CN103547597B (zh) 2017-03-15
PE20181076A1 (es) 2018-07-04
KR20140018905A (ko) 2014-02-13
TW201309729A (zh) 2013-03-01
IL254062A0 (en) 2017-10-31
US9914784B2 (en) 2018-03-13
CO6791571A2 (es) 2013-11-14
AU2017202934A1 (en) 2017-05-25
BR112013021134A2 (pt) 2016-11-29
NZ708615A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
HRP20201399T1 (hr) Novi modulatori i postupci njihove uporabe
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2014511179A5 (hr)
ES2686693T3 (es) Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones
ES2566602T3 (es) Anticuerpos anti-ErbB3
JP2017500028A5 (hr)
RU2019118359A (ru) Антитело к cd73 человека
JP2016531915A5 (hr)
HRP20191169T1 (hr) Konjugati antidll3-protutijelo-pbd i njihove uporabe
IL295230A (en) Combination therapy with anti-cd73 antibodies
JP2016513664A5 (hr)
JP2016536020A5 (hr)
JP2018127469A5 (hr)
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
HRP20211444T1 (hr) Anti-dll3 antitijelo
JP2018527919A5 (hr)
RU2014138041A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2016538318A5 (hr)
IL278574B1 (en) Compounds acting on glycans and methods of using them
JP2017535257A5 (hr)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2014534806A5 (hr)
RU2015144105A (ru) Антитела к гепсидину и их применения
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration